Teva’s $40 billion comeback brings Wall Street’s biggest prize into view...

Economics and markets | Jul 30, 2026, 9:36 AM

Teva Pharmaceutical Industries has reached a valuation above $40 billion following years of restructuring under CEO Richard Francis.

The generic-drug company’s improved performance has positioned it as a potential candidate for inclusion in the S&P 500 index.

PRO: see who's reacting and what you're missing. See the whole picture →